The History of Cystic Fibrosis by Dr James Littlewood OBE

Edited and produced by Daniel Peckham

 

1959 Lurie MH. Cystic fibrosis of the pancreas and the nasal mucosa. Ann Otol Rhinol Laryngol 1959; 68:478.[PubMed]

An early description of nasal polyps (figure 1) which are remarkably common in both children and adults with CF (6-48% in various series). In this paper three illustrative cases were described at an ENT meeting. (also Shwachman et al. 1962 below; Complete filling of the nasal sinuses was described by Pennington CL. AMA Arch Otolaryng 1956; 63:576; Bodian describes changes in the sinuses, (1952 above). Nasal polyposis may be the presenting feature of CF, the first evidence of CF being nasal polyps so large they are appearing at the external nares as occured in one of our Leeds children.

 

1961 Shwachman H, Kulczycki LL, Mueller HL. Nasal polyposis in patients with cystic fibrosis. Am J Dis Child 1961; 102:768-769.
An early description of nasal polyps (also Lurie MH, 1959 above). Of 650 patients with CF seen over the previous 4 years, 43 had nasal polyposis - 10% of those over 3 years. The effect on facial appearance, increasing the width of the nasal bridge, and the tendency to recur after removal were stressed. There was nothing characteristic about the histological appearance of the polyps. A sweat test was recommended in any child with nasal polyposis. (also Shwachman H. Kulczycki LL, Mueller HL, Flake CG. Nasal polyposis in patients with cystic fibrosis. Pediatrics 1962; 30: 389-401. [PubMed]).  Nasal polyposis occurring in 50 (6.7%) of 742 patients with CF in those with allergies and those without).


Later more accurate assessment of the incidence of polyps was possible with fibreoptic instruments indicating 37% of patients were affected. Inhaled steroids were used with some success as local treatment – eventually many years later confirmed as effective in a controlled trial (Hadfield et al, 2000 below). Also as an incidental finding during a trial of oral ibuprofen for the chest infection, the nasal polyps were observed to shrink in patient receiving this drug (Lindstrom et al, 2007 below).

 

 

Wang X. Moylan B. Leopold DA. Kim J. Rubenstein RC. Togias A. Proud D. Zeitlin PL. Cutting GR. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhino sinusitis in the general population. JAMA 2000; 284:1814-1819. [PubMed]
Eleven of 147 chronic rhino sinusitis (CRS) patients (7.5%) were found to have a CF mutation (DeltaF508, n = 9; G542X, n = 1; and N1303K, n = 1). Diagnostic testing excluded CF in 10 of these patients and led to CF diagnosis in 1. Excluding this patient from the analyses, the proportion of CRS patients who were found to have a CF mutation (7%) was significantly higher than in the control group (n = 2 [2%]; P =.04, both having DeltaF508 mutations). Furthermore, 9 of the 10 CF carriers had the polymorphism M470V, and M470V homozygotes were over represented in the remaining 136 CRS patients (P =.03).
These data indicate that mutations in the gene responsible for CF may be associated with the development of chronic rhinosinusitis in the general population. Another study suggesting that CF heterozygotes or even atypical patients with CF may be over represented in a condition with similar

clinical features to CF.

Fig. 1: Nasal polyps in cystic fibrosis

2000 Hadfield PJ, Rowe-Jones JM, Mackay IS. The prevalence of nasal polyps in adults with cystic fibrosis. Clin Otolaryngol Allied Sci 2000; 25:19-22.[PubMed]
The prevalence of nasal polyps in this endoscopic study of 211 adults with CF was 37%. The commonest nasal symptoms were discharge, headache and obstruction. Intranasal endoscopy usually demonstrated mucosal oedema and thin, clear discharge. The prevalence of allergy, as diagnosed by skin prick testing, was almost twice that of the general population. Tympanometry showed that middle ear effusion was uncommon in these patients.

Surprisingly, previous studies have also shown a low incidence of middle ear infection in people with CF (also Hadfield et al. 2000. below). Endoscopic studies are required to give an accurate estimate of the incidence of nasal polyps that may have been under-estimated in previous studies.

 

2000 Hadfield PJ, Rowe-Jones JM, Mackay IS. A prospective treatment trial of nasal polyps in adults with cystic fibrosis. Rhinology 2000; 38:63-65. [PubMed]
The first prospective, randomised, double-blind trial of the treatment of nasal polyps in cystic fibrosis. Use of betamethasone nasal drops showed a statistically significant reduction in polyp size in comparison to placebo treatment.

This is the first trial of topical steroid treatment of nasal polyps, a complication that can prove a troublesome and recurring problem for the patient. Inhaled steroids appeared to have some effect but they had never been the subject of a clinical trial. The recurrence rate after surgery is very high.
In a more recent study of the non-steroidal anti-inflammatory ibuprofen for CF lung disease, the drug had a favourable and quite unexpected effect on the nasal polyps which was noted as an incidental finding (Lindstrom D R, et al. J Otolaryngol 2007; 36:309-314. below [PubMed]).

 

2003 Bateman ND, Fahy C, Woolford TJ. Nasal polyps: still more questions than answers. J Laryngol Otol 2003; 117:1-9.[PubMed].
Nasal polyps are common, affecting one to four per cent of the population. Their cause, however, remains unknown and it is possible that it is not the same in all patients. They have a clear association with asthma, aspirin sensitivity and cystic fibrosis. Histologically they demonstrate large quantities of extracellular fluid, mast cell degranulation and an infiltrate of inflammatory cells, usually eosinophils. The authors believe that an endoscopic approach using a microdebrider facilitates accurate removal of polyps with preservation of normal anatomy.

This is a detailed review of polyps in general with no new information.

 

2007 Lindstrom DR, Conley SF, Splaingard ML, Gershan WM. Ibuprofen therapy and nasal polyposis in cystic fibrosis patients. J Otolaryngol 2007; 36:309-314.[PubMed]
Twelve of 22 patients with CF were treated with high-dose ibuprofen therapy to benefit their pulmonary function. Twelve had nasal polyposis and all 12 patients had observed absence of nasal polyps at some point during their ibuprofen course; nasal polyps were present in five patients during ibuprofen therapy, and all resolved with increased ibuprofen doses. Polyps occurred in six of eight patients after ibuprofen therapy ceased. Five of the 12 patients required endoscopic sinus surgery for polyposis.

This is an interesting incidental finding that oral ibuprofen improves nasal polyposis. This could prove very helpful in patients with severe and recurring nasal polyposis which can be a very difficult problem.

 

2009 Buyukozturk S. Gelincik A. Aslan I. Aydin S. Colakoglu B. Dal M. Methotrexate: can it be a choice for nasal polyposis in aspirin exacerbated respiratory disease?. J Asthma 2009; 46:1037-1041. [PubMed].
A report of two patients with asthma whose nasal polyps dramatically reduced in size after a course of methotrexate therapy administered as an additional treatment for their steroid- dependent asthma.

Although these patients had asthma and not CF it is interesting that they responded to methotrexate - it is possible that the minority of people with severe recurring nasal polyps may also respond.

 

2010 Rickert S, Banuchi VE, Germana JD, Stewart MG, April MM. Cystic fibrosis and endoscopic sinus surgery: Relationship between nasal polyposis and likelihood of revision endoscopic sinus surgery in patients with cystic fibrosis. Arch Otolaryngol 2010; 136:988- 992. [PubMed]

The authors graded the extent of nasal polyposis endoscopically in a cystic fibrosis population before the first surgical intervention, they observed the patients prospectively and recorded the need for revision endoscopic sinus surgery, and compared this among the individual polyp grading groupings. There were significant differences depending on the polyp grading - more polyps more recurrent surgery required.

Although the findings were to be expected they are included as there is relatively little published on sinus and polyp problems although they are a major chronic problem for many people with CF.

 

2013 Lavin J. Bhushan B. Schroeder JW Jr. Correlation between respiratory cultures and sinus cultures in children with cystic fibrosis. Int J Pediatr Otorhi 2013; 77:686-9.[PubMed]     Previous studies have had varying results on the correlation between respiratory and sinus cultures so further investigation is warranted. Bacterial growth from preoperative sputum, bronchoalveolar lavage, and oropharyngeal cultures were compared to the bacterial growth from intraoperative sinus cultures in patients with cystic fibrosis undergoing endoscopic sinus surgery.

In the patients over eight years of age, 16 of 26 sputum cultures matched sinus cultures (p=0.4). When sputum cultures with normal flora and no growth were eliminated, 16 of 21 matched sinus cultures (p=0.02). No statistically significant associations were found for sputum cultures in patients under eight years of age. No statistically significant associations were found between oropharyngeal or bronchoalveolar lavage cultures and intraoperative sinus cultures from patients of any age. When Staphylococcus aureus was cultured from sputum in patients over eight years of age the positive and negative predictive values that S. aureus would be cultured from the sinuses were 100% and 75% respectively. The positive and negative predictive values for Pseudomonas aeruginosa were 73% and 86% respectively.

The authors concluded that in children with CF who are over eight years of age, organisms grown from sputum cultures are similar to organisms grown from sinus cultures when bacterial growth is present.

 

2013 Lindig J. Steger C. Beiersdorf N. Michl R. Beck JF. Hummel T. Mainz JG. Smell in cystic fibrosis. Eur Arch Oto-Rhino-L 2013; 270:915-921. [PubMed]

In CF-associated smelling deficiencies are reported in between 12 and 71 % of patients. The aim of this study was to assess olfactory and gustatory function in relation to sinonasal symptoms and sinonasal colonization, and lung function and nutrition. Thirty-five CF patients of different ages were compared to 35 age-matched healthy controls. Olfactory function was assessed by 'Sniffin'Sticks', gustatory qualities by "Taste-strips", and symptoms by sino-nasal outcome test 20 (SNOT-20).

Normosmia was found in 62.8 % of healthy controls but only in 28.6 % of CF patients. In contrast the majority of CF patients exhibited a smell loss; almost 62.9 % of them were hyposmic, and 8.6 % functionally anosmic. Importantly, reduced olfactory function only affected odor thresholds, which were significantly increased in CF, not odor identification. This suggests that the olfactory dysfunction in CF results from the olfactory periphery due to either problems in conduction and/or a functional lesion due to the inflammatory process. SNOT-20 scores increased continuously from normosmic to hyposmic and anosmic CF patients (means 7.2/11.1/28.3 points). Neither sinonasal pathogen colonization, gender, pulmonary function, nor allergy or sinonasal surgery appeared to have significant effects on olfactory function and taste.

Olfactory disorders are considerably more frequent in CF patients than in age-matched healthy controls. Assessing these parameters within CF-routine care should be considered because of their importance to nutrition and, thus, overall therapy outcome.

This problem may be very relevant in people with CF and a contributory factor to poor appetite and inadequate dietary intake. As the condition in the upper respiratory tract nor treatment had a signifcant effect it is difficult to see how the situation could be improved. As more CF patients had reduced rather than absent sense, which affected only 8.6%, increasing the olfactory stimuli from food etc would presumably be a first step in improving the situation. However, a previous study found that nutritional status was unrelated to the sensation of smell (Aitken ML et al. Sensation of smell does not determine nutrional status in patients with cystic fibrosis.Pediatr Pulmonol 1997; 24:52-56. [PubMed]).

 

2013 Aanaes K. Johansen HK. Poulsen SS. Pressler T. Buchwald C. Hoiby N. Secretory IgA as a diagnostic tool for Pseudomonas aeruginosa respiratory colonization. J Cyst Fibros 2013; 12: 81-87. [PubMed]

Pseudomonas aeruginosa sinusitis may be the focus for intermittent lung colonization in patients with cystic fibrosis (CF). The sinusitis may induce elevated IgA levels in nasal secretion and saliva against P. aeruginosa.

120 CF patients chronically infected, intermittently colonized or without P. aeruginosa in the lungs participated in this cross-sectional study. IgA and IgG against P. aeruginosa sonicate and alginate were measured in nasal secretions, saliva, and in serum by ELISA.

RESULTS: The intermittently colonized patients had significantly higher IgA levels in nasal secretions and saliva than those without P. aeruginosa in the lungs, indicating that P. aeruginosa sinusitis may precede intermittent colonization and chronic infection of the lungs.

The authors conclude specific IgA against P. aeruginosa in nasal secretions and saliva can contribute to differentiation between patients chronically infected, intermittently colonized, and without P. aeruginosa in the lungs. The diagnostic value of the IgA ELISA awaits a prospective study.

The upper respiratory tract is receiving more attention as a source of organisms invading the lower airways – particularly P. aeruginosa. ELISA determined antibodies to P. aeruginosa have been used by some units for many years and found to be valuable in indicating the presence of Pseudomonas.

Summary of Kasper Aanaes’s Doctoral Thesis on this subject has been published and is fully referenced and liberally illustrated - “Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis. Aanaes K. J Cyst Fibros 2013; 12 (Suppl 2):S1-S20.

 

2013 Berkhout MC. Rijntjes E. El Bouazzaoui LH. Fokkens WJ. Brimicombe RW. Heijerman HG. Importance of bacteriology in upper airways of patients with Cystic Fibrosis. J Cyst Fibros 2013; 12:525-529. [PubMed]

Recently the influence of the upper airways (UAW) on the general health of a patient with Cystic Fibrosis (CF) has been acknowledged. Surprisingly the microbiology of the upper compartment of the airways receives barely any attention in the treatment of CF. The aim of the present study was to investigate the microbiology of the upper airways in adult patients with CF, to correlate these findings with cultures from the lower airways (LAW) and with clinical characteristics. In this cross-sectional study bacteriological and clinical data were gathered from 104 adult patients with CF. UAW samples for culture were collected by nasal lavage and middle meatal swabs; LAW cultures were performed on expectorated sputum or cough swabs. Each patient performed the Rhinosinusitis Outcome Measure (RSOM-31).

In 72 patients (69.2%) UAW cultures yielded micro organisms other than normal nasal flora and in 50 patients (48.1%) Pseudomonas aeruginosa grew from the UAW cultures. Similarity between UAW and LAW cultures was determined in 50.0% of these 72 patients. In 3 patients P. aeruginosa was cultured from the UAW after successful eradication of P. aeruginosa from the LAW. P. aeruginosa in the UAW did not influence symptoms of sinonasal disease compared to other micro organisms.

The authors concluded comparison of UAW and LAW cultures in adult patients with CF showed one or more concordant micro organism in 50.0% of the patients. P. aeruginosa was most frequently cultured from the UAW. P. aeruginosa can be cultured from the UAW after eradication therapy which may suggest persistence of P. aeruginosa in the UAW. We feel this is may be a motive to include the UAW in eradication therapy in Cystic Fibrosis.

Undoubtedly the upper airways are now receiving more attention as a potential reservoir of infection. The relationship between the cultures from the upper and lower airways is not surprising but the persistence even after P. aeruginosa eradication therapy certainly suggests more active measures would be appropriate. However, some years ago decontamination of the upper respiratory tract was attempted with regular polymyxin/tobramycin/amphotericin gel to treat patients newly colonised by P. aeruginosa infection but did not prove to be successful (Dalzell AM et al, 1990. [PubMed]).

 

 

2014 Di Cicco M. Alicandro G. Claut L. Cariani L. Luca N. Defilippi G. Costantini D. Colombo C. Efficacy and tolerability of a new nasal spray formulation containing hyaluronate and tobramycin in cystic fibrosis patients with bacterial rhinosinusitis. J Cyst Fibros 2014; 13(4):455-60. [PubMed]
A small study to assess the tolerability and efficacy of a nasal spray formulation containing 0.2% sodium hyaluronate and 3% tobramycin compared to a control formulation containing 0.2% sodium hyaluronate alone in the treatment of bacterial rhinosinusitis in patients with CF.
The formulation containing hyaluronate and tobramycin was more effective than hyaluronate alone in improving the status of the nasal mucosa, in reducing the mucopurulent secretion at the level of the osteomeatal complex and in improving ENT symptoms (hyposmia/anosmia and headache/facial pain).
The authors suggest that the present study suggests that the combination therapy with hyaluronate plus tobramycin was more effective than hyaluronate alone in the treatment of bacterial rhinosinusitis in CF.

 

2014 Hayes D Jr. McCoy KS. Sheikh SI. Improvement of sinus disease in cystic fibrosis with ivacaftor therapy. Am J Resp Crit Care Med 2014; 190(4):468. [PubMed]

A 19-year old woman with CF (d508/G551D) experienced significant general improvement after 15 months ivacaftor therapy and in particular major improvement in previously troublesome sinus disease. Impressive changes in the MCT scan reproduced in the link from the abstract.

 

 

2014 Lourenco BM. Costa KM. da Silva Filho M. Voice disorder in cystic fibrosis patients. ONE [Electronic Resource]. 9(5):e96769, 2014 [PubMed]
The authors tested vocal parameters, using both objective physical measures and the GRBAS subjective evaluation method, in male and female cystic fibrosis patients undergoing conventional treatment and compared them to age and sex matched controls. They found that cystic fibrosis patients had a significantly lower vocal intensity and harmonic to noise ratio, as well as increased levels of jitter and shimmer. In addition, cystic fibrosis patients also showed higher scores of roughness, breathiness and asthenia, as well as a significantly altered general grade of dysphonia. When they segregated the results according to sex, we observed that, as a group, only female cystic fibrosis patients had significantly lower values of harmonic to noise ratio and an abnormal general grade of dysphonia in relation to matched controls, suggesting that cystic fibrosis exerts a more pronounced effect on vocal parameters of women in relation to men.
Overall, the dysphonic characteristics of CF patients can be explained by dysfunctions in vocal fold movement and partial upper airway obstruction, potentially caused by the accumulation of mucus and chronic cough characteristic of CF symptomatology. These results show that CF patients exhibit significant dysphonia and suggest they may potentially benefit from voice therapy as a parallel treatment strategy.

 

With the intrinsic mucosal abnormalities and long term inhalation therapy advised, it is not surprising there are minor voice abnormalities in many people with CF.

 

2014 Mainz JG. Schien C. Schiller I. Schadlich K. Koitschev A. Koitschev C. Riethmuller J. Graepler-Mainka U. Wiedemann B. Beck JF. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. J Cyst Fibros 2014; 13:461-70. [PubMed]
Either dornase alfa (Pulmozyme) or isotonic saline were inhaled for 28 days with the Pari-Sinus and after 28 days (wash-out) crossed over to the alternative treatment. Primary nasal symptoms improved significantly with dornase alfa compared with no treatment, while small improvements with isotonic saline did not reach significance.
Vibrating sinonasal inhalation of dornase alfa reduces rhino sinusitis symptoms in CF and also incidentally improved lung function.

 

 
2015 Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R.  High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. J Cyst Fibros 2015; 14(2):248-54. [PubMed]
Intravenous aminoglycoside (IV AG) antibiotics have ototoxic complications in some patients. Audiological monitoring, if performed, uses only standard pure-tone audiometry (PTA). This study determined the most appropriate audiological tests and to identify possible risk factors. Auditory assessment was performed using standard pure tone audiometry (PTA), extended high-frequency (EHF) audiometry and distortion-product otoacoustic emissions (DPOAE).
70 CF children, mean (SD) age 10.7 (3.5) years, were recruited. Of the 63 children who received IV AG, 15 (24%) children had ototoxicity detected by EHF audiometry and DPOAE.
Standard PTA only detected ototoxicity in 13 children. Eleven of these children had received at least 10 courses of IV AG courses. A 25 to 85 dBHL hearing loss (mean+/-SD: 57.5+/-25.7 dBHL) across all EHF frequencies and a significant drop in DPOAE amplitudes at frequencies 4 to 8 kHz were detected. However, standard PTA detected a significant hearing loss (>20 dBHL) only at 8 kHz in 5 of these 15 children and none in 2 subjects who had significantly elevated EHF thresholds. The number of courses of IV AG received, age and lower lung function were shown to be risk factors for ototoxicity. CF children who had received at least 10 courses of IV AG had a higher risk of ototoxicity.
Extended high frequency audiometry identified 2 more children with ototoxicity than standard PTA and depending on facilities available, should be the test of choice for detecting ototoxicity in children with CF receiving IV aminoglycosides.

 

2015 Farzal Z, Kou YF, St John R, Shah GB, Mitchell RB. The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review. Laryngoscope. 2015 Jul 7. doi: 10.1002/lary.25409. [Epub ahead of print] [PubMed]
Study to review the role of routine hearing screening for sensorineural hearing loss (SNHL) in children with cystic fibrosis (CF) who have been on aminoglycoside therapy.
Twelve studies (1979-2014) were reviewed. The study population included 762 children (5 months-20 years). Hearing screening measures included pure-tone audiometry (PTA) at standard ± high frequency threshold (HFPTA) (12/12), distortion product otoacoustic emissions (DPOAE) (4/12), transient-evoked otoacoustic emissions (1/12), and automated auditory brainstem response (1/12).
The overall prevalence of sensory neural hearing loss ranged from 0% to 29%. However, on subset analysis of children with greater than 10 courses of intravenous (IV) aminoglycosides, up to 44% had sensory neural hearing loss. Eight studies recommended hearing screening in CF children on aminoglycosides; of these, two studies recommended screening even without aminoglycoside exposure, and four studies made no recommendations. HFPTA was the most commonly recommended screening measure followed by DPOAEs.
 
- This systematic review supports a recommendation for clinicians to arrange for routine hearing screening in children with CF during and after aminoglycoside exposure based on the high prevalence of sensorineural hearing loss this population. They suggest future studies should define the optimal timing for hearing screening during and after aminoglycoside therapy in children with CF.

 


2015 Willis J, Michael DD, Boyer H, Misono S. Prevalence and Severity of Dysphonia in Patients with Cystic Fibrosis: A Pilot Study. Otolaryngol Head Neck Surg. 2015 Jul;153(1):88-93. doi: 10.1177/0194599815581832. Epub 2015 Apr 27.[PubMed]

A study to assess the prevalence and severity of dysphonia in patients with cystic fibrosis sinusitis.  Cystic fibrosis sinusitis appeared to be associated with worse vocal function as measured by patient self-report as well as auditory-perceptual evaluation of voice compared with patients with non-CF sinusitis and healthy controls.


 
2015 Mainz JG, Gerber A, Lorenz M, Michl R, Hentschel J, Nader A, Beck JF, Pletz MW, Mueller AH. Pseudomonas aeruginosa Acquisition in Cystic Fibrosis Patients in Context of Otorhinolaryngological Surgery or Dentist Attendance: Case Series and Discussion of Preventive Concepts. Case Rep Infect Dis 2015;2015:438517. doi: 10.1155/2015/438517. Epub 2015 Mar 18 [PubMed]

For their almost regular sinonasal involvement, CF patients often require otorhinolaryngological (ORL) attendance. Despite some fields around ORL-procedures with comparable risk for acquisition of P. aeruginosa as dental procedures, such CF cases have not yet been reported. The authors present four CF patients, who primarily acquired P. aeruginosa around ORL surgery, and one around dentist treatment. Perils include contact to pathogen-carriers in waiting rooms, instrumentation, suction, drilling, and flushing fluid, when droplets containing pathogens can be nebulized. Postsurgery mucosal damage and debridement impair sinonasal mucociliary clearance, facilitating pathogen proliferation and infestation.
They suggest that sinonasal surgery and dentist treatment of CF patients without chronic P. aeruginosa colonisation must be linked to repeated microbiological assessment. Further studies must elaborate whether all CF patients undergoing ORL-surgery require anti-pseudomonal prophylaxis, including nasal lavages containing antibiotics. Altogether, this underestimated risk requires structured prevention protocols.
 
- There is increasing interest in the upper respiratory tract and its relation to lower airways infection, in particular as a source of infection.The risks from dental equipment have been known for many years first from Copenhagen (Jensen ET et al. J Hosp Infect 1997; 36(2): 117-122. [PubMed]) but the the possibility of other upper respiratory tract procedures determining the onset of P. aeruginosa infection is obviously important.

 

 

2015 Lo DK, Hurley MN, Muhlebach MS, Smyth AR.  Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.  Cochrane Database Syst Rev. 2015 Feb 24;2:CD009650. doi: 10.1002/14651858.CD009650.pub3. [PubMed]
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a potentially harmful pathogen in cystic fibrosis, and has been increasing steadily in prevalence internationally. Chronic pulmonary infection with MRSA is thought to confer cystic fibrosis patients with a worse overall clinical outcome and, in particular, result in an increased rate of decline in lung function. Clear guidance for the eradication of MRSA in cystic fibrosis, supported by robust evidence from good quality trials, is urgently needed.
To evaluate the effectiveness of treatment regimens designed to eradicate MRSA and to determine whether the eradication of MRSA confers better clinical and microbiological outcomes for people with cystic fibrosis.  There were no eligible trials for inclusion.  Although the results of several non-randomised studies would suggest that, once isolated, the eradication of MRSA is possible; whether this has a significant impact on clinical outcome is still unclear.

Update of Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. [Cochrane Database Syst Rev. 2013]